

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (canceled)

Claim 2 (previously presented): An isolated mammalian glycosylated bikunin, wherein the glycosylated bikunin is a placental bikunin and comprises at least one sialic acid residue.

Claims 3-5 (canceled)

Claim 6 (original): The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2,3) linkage.

Claim 7 (original): The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2,6) linkage.

Claim 8 (original): The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2,3) linkage and at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2,6) linkage.

Claim 9 (original): The glycosylated bikunin of claim 2 in a pharmaceutically acceptable carrier.

Claims 10-14 (canceled)

Claim 15 (previously presented): An isolated mammalian glycosylated monokunin, wherein the glycosylated monokunin is a placental monokunin and comprises at least one sialic acid residue.

Claims 16-17 (canceled)

Claim 18 (original): The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2,3) linkage.

Claim 19 (original): The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2,6) linkage.

Claim 20 (original): The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2,3) linkage and at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2,6) linkage.

Claim 21 (original): The glycosylated monokunin of claim 15 in a pharmaceutically acceptable carrier.

Claims 22-24 (canceled)

Claim 25 (previously presented): The glycosylated bikunin of claim 2, wherein the glycosylated bikunin comprises at least one N-acetylneuraminic acid residue.

Claim 26 (previously presented): The glycosylated monokunin of claim 15, wherein the glycosylated monokunin comprises at least one N-acetylneuraminic acid residue.